section name header

Pronunciation

ben-AYE-ze-pril

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: ace inhibitors

Indications

REMS


Action

  • Angiotensin-converting enzyme (ACE) inhibitors block the conversion of angiotensin I to the vasoconstrictor angiotensin II. ACE inhibitors also prevent the degradation of bradykinin and other vasodilatory prostaglandins. ACE inhibitors also plasma renin levels and aldosterone levels. Net result is systemic vasodilation.
Therapeutic effects:
  • Lowering of BP in patients with hypertension.

Pharmacokinetics

Absorption: 37% absorbed after oral administration.

Distribution: Crosses the placenta; enters breast milk in small amounts.

Protein Binding: 95%.

Metabolism/Excretion: Converted by the liver to benazeprilat, the active metabolite; 20% excreted in urine; 11–12% nonrenal (biliary) elimination.

Half-Life: Benazeprilat: 10–11 hr.

Time/Action Profile

(antihypertensive effect)

ROUTEONSETPEAKDURATION
POwithin 1 hr*1–2 wks24 hr



*After single dose.

Chronic dosing.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension

Derm: rash

F and E: hyperkalemia

GI: nausea

GU: impaired renal function

Neuro: fatigue, dizziness, drowsiness, headache

Resp: cough

Misc: ANGIOEDEMA

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Lotensin